Allozymes is applying innovative ultrahigh-throughput microfluidics technology to accelerate enzyme evolution and development. The company’s first target application is to transform ingredients manufacturing for industries ranging from pharmaceuticals and cosmetics to food and beverages.
Allozymes says it is capable achieving 10X faster and cheaper enzyme development with 200X higher chance of success and 1,000,000X less reagent consumption.
Founded in 2020 in Singapore, Allozymes is a graduate of the Entrepreneur First program which brings together talented founders and supports them at the earliest stages of company formation. The company’s Co-Founder and CTO Akbar Vahidi invented allozymes’ technology when he was serving as a lead research fellow at the National University of Singapore (NUS). Co-Founder and CEO Peyman Salehian also has a PhD from NUS, as well as extensive experience in transferring technologies from lab to the market.
Subscribe for alerts on new companies featured on Startups.Bio
Aulos Bioscience aims to revolutionize cancer patient care through the development of pioneering Interleukin-2 therapeutics for the treatment of solid tumor cancers. Interleukin-2 or IL-2 …
Code Bio is using its novel targeted non-viral delivery platform to develop genetic medicines for serious and life-threatening diseases such as Type 1 Diabetes and …
Muna Therapeutics aims to preserve brain function and enhance resilience to neurodegenerative diseases. The company engages in the discovery and development of novel therapies that …
Glyphic Biotechnologies is an MIT spin-out aiming to accelerate the critical but slow step of sequencing new proteins, potentially cutting drug development times down by …
ImmuneID is a precision immunology company that has developed a genome-wide, high-throughput platform to provide an understanding of individual immune responses. ImmuneID's aiSPIRE platform screens billions of …
Flare uses a “switch-site based drug discovery approach” to develop a pipeline of therapeutic programs that target pivotal cancer drivers such as transcription factor dysregulation …